Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Mimedx Group, Inc. Announces Publication of Peer-Reviewed Study in Facial Plastic Surgery & Aesthetic Medicine Investigating the Safety and Utility of PURION Processed dHACM for Use in Mohs Micrographic Surgeries

11/17/2021 | 08:00am EST

MiMedx Group, Inc. announced publication of a peer-reviewed study in Facial Plastic Surgery & Aesthetic Medicine investigating the safety and utility of the Company?s PURION processed dHACM for use in Mohs micrographic surgeries. The retrospective propensity score-matched case-control study demonstrated that PURION processed dHACM placental allografts were associated with a statistically significant lower risk for infection, poor scar cosmesis, scar revision, and additional operation at the index site, when compared to traditional methods of incisional repair. The findings indicate that placental allografts may be a viable alternative to autologous tissue-based reconstruction, including flaps and full-thickness skin grafts (FTSG), particularly in an aging population undergoing numerous Mohs procedures in moderate to high-risk areas of the face, head, neck, and dorsal hand. Mohs micrographic surgery is considered the most effective technique for treating many basal and squamous cell carcinomas, the two most common types of non-melanoma skin cancer. With the incidence of NMSC increasing rapidly in people over 65, Mohs has become a common procedure to remove these cutaneous malignancies. In some cases, lesions occur multiple times in a localized region and repeat surgery to remove them impacts quality and availability of nearby autologous tissue, thereby impacting the aesthetic and functional success of graft or flap procedures. To complicate matters, tumors among the elderly are often more invasive, and obtaining cancer-free margins can result in significant tissue loss, which further increases the need to consider alternative tissue sources. The retrospective, case-controlled study patient population included 143 propensity score-matched pairs undergoing MMS for a basal or squamous cell carcinoma on the face, head, neck, or dorsal hands with same-day reconstruction using either autologous tissue or dHACM placental allograft, between January 2014 and December 2018. The size, location, and reconstructive complexity of defects repaired by both approaches were equivalent. The study compared a variety of post-surgical medical complications, such as infection, bleeding, dehiscence, additional operation and development of a non-healing wound, as well as cosmetic outcome measures, including suboptimal scarring and scar revision or treatment. Patients who received placental allografts were 12 times less likely to have a post-surgical infection or require additional surgery, and 19 times less likely to have unacceptable scarring. A significantly greater proportion of patients in the placental allograft group (97.9%) experienced zero postoperative complications compared to patients undergoing autologous tissue-based repairs. Placental allograft cases developed less infection than their flap and FTSG counterparts, and no instances of bleeding, dehiscence, non-healing wounds, scar revision, additional operation at the index site, or poor scar cosmesis were observed. These findings support the potential for use of the Company?s PURION processed dHACM placental allografts as an alternative to existing methods for reconstructive repair in Mohs procedures, particularly in older patients with moderate to high-risk defects.

© S&P Capital IQ 2021
All news about MIMEDX GROUP, INC.
01/10MIMEDX GROUP, INC. : Results of Operations and Financial Condition, Regulation FD Disclosu..
01/10MIMEDX Outlines Key Strategic Milestones for 2022
01/10MiMedx Group, Inc. Provides Revenue Guidance for the Financial Year 2022
01/04MIMEDX to Participate at the H.C. Wainwright BioConnect Virtual Conference
2021MIMEDX to Present at the 40th Annual J.P. Morgan Healthcare Conference
2021MIMEDX GROUP, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K..
2021MiMedx Lifts Adjusted Net Sales Outlook for FY21
2021MIMEDX Outlines Long-Term Value Creation Strategy at Virtual Investor Day
2021Mimedx Group, Inc. to Provide New Details About Near- and Long-Term Growth Opportunitie..
2021MIMEDX Announces Speakers for December 7 Investor Day
More news
Analyst Recommendations on MIMEDX GROUP, INC.
More recommendations
Financials (USD)
Sales 2021 255 M - -
Net income 2021 -19,0 M - -
Net Debt 2021 - - -
P/E ratio 2021 -26,6x
Yield 2021 -
Capitalization 502 M 502 M -
Capi. / Sales 2021 1,97x
Capi. / Sales 2022 1,88x
Nbr of Employees 735
Free-Float 96,6%
Duration : Period :
MiMedx Group, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MIMEDX GROUP, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 2
Last Close Price 4,52 $
Average target price 14,17 $
Spread / Average Target 213%
EPS Revisions
Managers and Directors
Timothy R. Wright Chief Executive Officer & Director
Peter M. Carlson Chief Financial Officer
M. Kathleen Behrens Wilsey Chairman
David H. Mason Chief Medical Officer
Robert Benjamin Stein Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
MIMEDX GROUP, INC.-25.17%502
MODERNA, INC.-38.99%62 828
LONZA GROUP AG-20.54%48 784